| Politician | Action | Description | Traded |
|---|---|---|---|
| Sell | GILEAD SCIENCES CMN | Jun 16, 2026 | |
| Buy | Gilead Sciences, Inc. | May 6, 2026 | |
| Buy | Gilead Sciences, Inc. | May 6, 2026 | |
| Buy | GILEAD SCIENCES INC CMN CLAS | Apr 24, 2026 | |
| Buy | GILEAD SCIENCES INC | Mar 29, 2026 | |
| Buy | Gilead Sciences, Inc. | Mar 27, 2026 | |
| Buy | GILEAD SCIENCES INC CMN | Feb 24, 2026 | |
| Sell | GILEAD SCIENCES INC CMN | Feb 5, 2026 | |
| Sell | GILEAD SCIENCES, INC. CMN | Jan 29, 2026 | |
| Buy | GILEAD SCIENCES INC. CMN | Jan 29, 2026 |
This page tracks congressional stock trading activity in Gilead Sciences, Inc. (GILD) in the Healthcare sector. Disclosed Capitol has indexed 266 disclosed congressional trades involving GILD. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of August 2026 — Disclosed Capitol has tracked 266 disclosed congressional trades in Gilead Sciences, Inc. (GILD) — 120:80 sell-heavy ratio — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Jun 16, 2026 | Ro Khanna | D | Sell | $15,001 - $50,000 |
| May 6, 2026 | Jared Moskowitz | D | Buy | $1,001 - $15,000 |
| May 6, 2026 | Jared Moskowitz | D | Buy | $1,001 - $15,000 |
| Apr 24, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Mar 29, 2026 | Michael McCaul | R | Buy | $15,001 - $50,000 |
| Mar 27, 2026 | Alan Armstrong | R | Buy | $1,001 - $15,000 |
| Feb 24, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Feb 5, 2026 | Ro Khanna | D | Sell | $1,001 - $15,000 |
| Jan 29, 2026 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Jan 29, 2026 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
Across the 266 disclosed congressional trades in Gilead Sciences, Inc. (GILD), members of Congress have reported 80 buys and 120 sells. The average 30-day alpha vs. the S&P 500 is -1.07%.
As of September 2025, Gilead Sciences, Inc. has 64 federal contract award records on file from USAspending.gov — most recently -$4.4M from the Department of Health and Human Services on 2025-09-30.
| Award date | Agency | Amount |
|---|---|---|
| 2025-09-30 | Department of Health and Human Services · Office of the Assistant Secretary for Administration | -$4.4M |
| 2025-09-29 | Department of Health and Human Services · Office of the Assistant Secretary for Administration | -$5.1M |
| 2024-01-11 | Department of Veterans Affairs | -$54K |
| 2023-10-05 | Department of Veterans Affairs | $308K |
| 2023-04-11 | Department of Veterans Affairs | -$282K |
| 2023-02-06 | Department of Veterans Affairs | -$210K |
| 2022-10-01 | Department of Veterans Affairs | -$373K |
| 2022-08-10 | Department of Health and Human Services · Indian Health Service | -$3.9M |
| 2022-08-05 | Department of Veterans Affairs | $288K |
| 2022-07-08 | Department of Veterans Affairs | $393K |
Negative amounts are contract de-obligations. Browse and filter every award on the government contracts page.
For fiscal year 2025, Gilead Sciences, Inc. reported revenue of $29.44B and net income of $8.51B, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $7.80B, net income -$10.50B.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.